This technology is a pharmaceutical composition that prevents and treats urinary tract infections (UTIs) by eradicating uropathogenic E. coli, the primary cause of UTIs, using a specific ratio of caprylic acid and cranberry. Caprylic acid, a medium-chain fatty acid, significantly boosts the antibacterial effects of cranberry, allowing for effective bacterial control with short-term treatment.
Most UTIs are caused by E. coli. While antibiotic treatment is fast, it can lead to antibiotic resistance and is often difficult to use in patients with weakened immune systems. Cranberry, often used as a dietary supplement, is known to prevent bacteria from adhering to the urinary tract, but its standalone efficacy is minimal and requires long-term consumption, making it difficult to use for effective prevention or treatment.
This technology adds naturally derived caprylic acid, a listed food additive, to cranberry to enable the complete eradication of uropathogenic E. coli, including both initial and resident bacteria that attach to the urinary tract wall and penetrate the mucosa. The scope of the patent also includes methods for preventing and improving UTIs in non-human animals through short-term treatment. It can be applied to cranberry-based beverages and health supplements for UTI prevention, as well as alternative urological treatments and pet urinary health products, effectively elevating the benefits of cranberry to a clinical sterilization level without the risk of antibiotic resistance.
N/A
